Skip to content

Michael Wolff Jensen resigns from the Vicore board of directors and is replaced by Jacob Gunterberg as chairman of the board up until the annual general meeting in May 2022

Gothenburg, March 23, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (ATRAGs), today announces that Michael Wolff Jensen has resigned from the board of directors.

Michael Wolff Jensen, who has been the chairman of the board of directors of Vicore Pharma Holding AB (publ) since 2020, has today informed the board of directors of his resignation as chairman and member of the board of directors due to personal reasons.

Michael will leave Vicore’s board of directors with immediate effect. For the period of time up until the annual general meeting in May 2022, the board has today elected Jacob Gunterberg as new chairman of the board of directors.

“On behalf of the board and the shareholders, I would like to express a sincere thank you to Michael for his work as chairman of Vicore’s board”, says Jacob Gunterberg, newly elected chairman of the board.

For further information, please contact:
Nina Carlén, Chief Administrative Officer
Phone: +46 76-390 94 04

Jacob Gunterberg, Chairman of the board
Phone: +46 70 975 98 58

This information was submitted for publication on March 23, 2022 at 21:55 CET.

Source: Vicore Pharma